Erste Asset Management GmbH Reduces Holdings in Pfizer Inc. (NYSE:PFE)

Erste Asset Management GmbH reduced its holdings in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 25.0% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 432,299 shares of the biopharmaceutical company's stock after selling 144,444 shares during the period. Erste Asset Management GmbH's holdings in Pfizer were worth $11,507,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. Swedbank AB lifted its holdings in shares of Pfizer by 0.7% in the third quarter. Swedbank AB now owns 5,745,831 shares of the biopharmaceutical company's stock worth $166,284,000 after buying an additional 37,636 shares in the last quarter. United Bank lifted its stake in Pfizer by 3.7% in the 3rd quarter. United Bank now owns 35,599 shares of the biopharmaceutical company's stock worth $1,030,000 after purchasing an additional 1,277 shares in the last quarter. Entropy Technologies LP bought a new position in shares of Pfizer during the 3rd quarter valued at about $860,000. GSA Capital Partners LLP grew its position in shares of Pfizer by 87.6% during the third quarter. GSA Capital Partners LLP now owns 32,786 shares of the biopharmaceutical company's stock valued at $949,000 after purchasing an additional 15,310 shares in the last quarter. Finally, OVERSEA CHINESE BANKING Corp Ltd increased its holdings in shares of Pfizer by 52.6% in the third quarter. OVERSEA CHINESE BANKING Corp Ltd now owns 31,723 shares of the biopharmaceutical company's stock worth $919,000 after purchasing an additional 10,938 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors.

Pfizer Trading Down 0.4 %

Shares of NYSE:PFE opened at $25.60 on Friday. The company has a market capitalization of $145.08 billion, a PE ratio of 18.16, a P/E/G ratio of 0.64 and a beta of 0.61. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. Pfizer Inc. has a 12-month low of $24.48 and a 12-month high of $31.54. The business's fifty day simple moving average is $26.26 and its 200-day simple moving average is $27.17.

Remove Ads

Pfizer (NYSE:PFE - Get Free Report) last announced its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, beating the consensus estimate of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The company had revenue of $17.76 billion during the quarter, compared to the consensus estimate of $17.26 billion. During the same period last year, the firm earned $0.10 earnings per share. Pfizer's revenue was up 24.7% compared to the same quarter last year. As a group, equities research analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Analysts Set New Price Targets

PFE has been the subject of a number of research reports. Bank of America reiterated a "neutral" rating and set a $29.00 target price on shares of Pfizer in a research report on Tuesday, December 10th. Hsbc Global Res upgraded shares of Pfizer to a "strong-buy" rating in a research report on Monday. StockNews.com downgraded shares of Pfizer from a "strong-buy" rating to a "buy" rating in a report on Wednesday, November 20th. Guggenheim reaffirmed a "buy" rating on shares of Pfizer in a report on Wednesday. Finally, Citigroup reduced their price objective on Pfizer from $30.00 to $29.00 and set a "neutral" rating on the stock in a research note on Tuesday, January 28th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating, six have assigned a buy rating and three have issued a strong buy rating to the stock. According to data from MarketBeat, Pfizer currently has an average rating of "Moderate Buy" and an average price target of $31.92.

Insider Buying and Selling at Pfizer

In other news, Director Ronald E. Blaylock acquired 19,457 shares of Pfizer stock in a transaction dated Thursday, February 13th. The stock was purchased at an average cost of $25.65 per share, for a total transaction of $499,072.05. Following the completion of the purchase, the director now directly owns 27,707 shares in the company, valued at $710,684.55. This trade represents a 235.84 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 0.06% of the stock is currently owned by company insiders.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.